NANOBIOTIX S.A. SP.ADR (5NRA) - Total Assets
Based on the latest financial reports, NANOBIOTIX S.A. SP.ADR (5NRA) holds total assets worth €67.76 Million EUR (≈ $79.22 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NANOBIOTIX S.A. SP.ADR balance sheet quality to measure how much of total assets are equity-financed.
NANOBIOTIX S.A. SP.ADR - Total Assets Trend (2021–2025)
This chart illustrates how NANOBIOTIX S.A. SP.ADR's total assets have evolved over time, based on quarterly financial data. Explore NANOBIOTIX S.A. SP.ADR long-term investment intensity to see how much of total assets are deployed in long-term investments.
NANOBIOTIX S.A. SP.ADR - Asset Composition Analysis
Current Asset Composition (December 2025)
NANOBIOTIX S.A. SP.ADR's total assets of €67.76 Million consist of 92.6% current assets and 7.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 77.9% |
| Accounts Receivable | €2.14 Million | 3.2% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €10.00K | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how NANOBIOTIX S.A. SP.ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NANOBIOTIX S.A. SP.ADR stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NANOBIOTIX S.A. SP.ADR's current assets represent 92.6% of total assets in 2025, an increase from 91.4% in 2021.
- Cash Position: Cash and equivalents constituted 77.9% of total assets in 2025, down from 82.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 3.2% of total assets.
NANOBIOTIX S.A. SP.ADR Competitors by Total Assets
Key competitors of NANOBIOTIX S.A. SP.ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Hugel Inc
KQ:145020
|
Korea | ₩1.13 Trillion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
NANOBIOTIX S.A. SP.ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.09 | 1.04 | 1.42 |
| Quick Ratio | 1.09 | 1.04 | 1.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.24 Million | €2.53 Million | €23.94 Million |
NANOBIOTIX S.A. SP.ADR - Advanced Valuation Insights
This section examines the relationship between NANOBIOTIX S.A. SP.ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 63.41 |
| Latest Market Cap to Assets Ratio | 17.88 |
| Asset Growth Rate (YoY) | 0.5% |
| Total Assets | €67.76 Million |
| Market Capitalization | $1.21 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values NANOBIOTIX S.A. SP.ADR's assets at a significant premium (17.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: NANOBIOTIX S.A. SP.ADR's assets grew by 0.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for NANOBIOTIX S.A. SP.ADR (2021–2025)
The table below shows the annual total assets of NANOBIOTIX S.A. SP.ADR from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €67.76 Million ≈ $79.22 Million |
+0.51% |
| 2024-12-31 | €67.42 Million ≈ $78.82 Million |
-28.20% |
| 2023-12-31 | €93.90 Million ≈ $109.78 Million |
+57.10% |
| 2022-12-31 | €59.77 Million ≈ $69.88 Million |
-41.27% |
| 2021-12-31 | €101.77 Million ≈ $118.98 Million |
-- |
About NANOBIOTIX S.A. SP.ADR
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more